• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1263764 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
5 B* n, x3 h% r! z' a* I9 |NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
# t" s% F4 [; `, S: o+ Author Affiliations3 K0 a- b. D! W# t5 a. A
  V( j( A) `5 \" M% ~5 g+ x
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan # q* |/ h# ^% O4 m- c& p9 R
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " I! _2 \( z) p3 I& h* ~
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
7 B6 B1 f+ n, A$ U2 v4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan 3 a/ @1 z* _( ~6 B# S
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 0 H& o$ V9 ?7 @6 ^* d. B+ r1 C2 ]
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ( U: O7 |  M  b2 P7 t% O
7Kinki University School of Medicine, Osaka 589-8511, Japan " e) m1 L- Q4 x, w' X6 L
8Izumi Municipal Hospital, Osaka 594-0071, Japan
; K$ `3 V+ e% A6 |3 `4 e9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
# u) z& P4 a/ k3 I( O# p  dCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
8 L( Q6 ~, S3 ^, k/ tAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
, S6 A7 U9 m& E/ t3 W; o% x1 E6 b+ I% l- t0 d
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type 0 \! L* B- z2 b+ J3 o% n& Y4 P/ y* d
0 m  H; {/ O/ ?0 b5 L1 j1 \  S
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
7 ^- ]. _& F' L8 w# @9 Z  d2 n2 C$ {9 L' u
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  ) O/ c  t$ t( J5 I

2 q2 Z+ N0 T" P. E$ I. O& U- aPublished online on: Thursday, December 1, 2011 2 A5 [8 H; Y0 d& v/ C3 b
$ X- d% t+ @- Y9 P7 ~
Doi: 10.3892/ol.2011.507 , M3 h# z& G& j! K4 O, g. T0 ?
/ r6 r" {/ b; ^; Q5 `
Pages: 405-410
: f+ r# l+ u3 g3 S  C% `
& x/ \% `, g4 Q3 }1 P" ~4 \Abstract:2 I) s, `0 {  C, X: H
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.  W. {# _+ U% O- Z4 F
5 [* ?- e$ C$ D
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
; p( Y! Z; A+ F' l* U$ jF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 3 b  v$ B3 ~# G8 _$ }
+ Author Affiliations
7 G0 u* A1 f8 l( V/ t* i1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
7 U' @  C6 D- e" V5 i2Department of Thoracic Surgery, Kyoto University, Kyoto 3 D# T. u  K. c  R$ {- _' a
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
* i& k, X1 R3 Z8 r&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
4 t* d4 [, m$ e$ z% Q. ^Received September 3, 2010.
' M7 q* T+ c7 V% o7 n' p6 sRevision received November 11, 2010.
% b* V. [" ~4 a$ k$ |- d4 P4 RAccepted November 17, 2010.
  e) `! n- [5 A) N5 XAbstract" h  |7 C# |5 V* C3 D. A3 R
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
* C( c3 c% C& qPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
0 C# v  H- ^+ c% V" X  [Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 5 p7 M6 s( _7 A0 E
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
7 a$ i. P* e' E; Z
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
) S+ u0 F! U& n& @7 N) N$ i今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?
7 b* k( [6 h0 v) J6 `
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
4 C6 F: H" W# ~9 H% D# Q# Bhttp://clinicaltrials.gov/ct2/show/NCT015235871 y& |! g* h( S9 r4 Q
. f. [& i. b8 C& `% J6 c* \7 s
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
/ H/ C  w: `7 W+ A. Jhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 / E% v* R9 K! r6 x8 P

0 F* k3 H" V1 S2 j2 A7 `( ?  q从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。) h4 }! x  A( u8 b$ P; u. W/ u4 t
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
5 J* y- a5 M5 Y  N从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。: Q' ?% U( o1 N3 A( ?1 O) `. y5 U* I
至今为止,未出 ...

( G1 k5 F& K; v! s( z- X6 ^5 b. N没有副作用是第一追求,效果显著是第二追求。" ]" ^+ f1 \( Z4 u! Z
不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表